|
Jul 1
|
3 UK Growth Companies With Up To 25% Insider Ownership
|
|
Jun 30
|
Faron Pharmaceuticals Ltd: Director/PCA Dealing
|
|
Jun 30
|
UK Growth Companies With Strong Insider Confidence In June 2025
|
|
Jun 30
|
Faron-Supported Research in Theranostics Identifies Secreted Clever-1 (sClever-1) as an Independent Driver of Immune Evasion in Cancer, Deepening the Understanding of Bexmarilimab’s Mode of Action
|
|
Jun 26
|
Exploring High Growth Tech Stocks in the UK for June 2025
|
|
Jun 25
|
UK Insider-Owned Growth Stocks For June 2025
|
|
Apr 24
|
Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025
|
|
Jan 9
|
Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
|
|
Dec 7
|
Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine
|